About INT

Innovative NeuroTechnologies, Inc. (INT) is a development-stage biotechnology company operating in “virtual mode” that is currently pursuing a pipeline of novel biologically-based therapeutic solutions to prevent, delay, or ameliorate the cognitive decline associated with neurodegenerative tauopathies, including:

Alzheimer’s disease (AD),

Frontotemporal dementia (FTD) or Pick’s disease,

Chronic traumatic encephalopathy (CTE) or dementia pugilistica,

Progressive supranuclear palsy (PSP),

Corticobasal degeneration (CBD)

Familial form of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).

The pathology of these seemingly disparate conditions is similar in that they involve dysregulation of the Tau protein and development of neurofibrillary tangles (NFTs), synaptic dysfunction, and/or neuronal loss, which underlie the observed dementia or cognitive deficits.  Unfortunately, there are no effective therapies presently available for this spectrum of disorders, and neurodegenerative tauopathies remain a very significant socioeconomic burden and tremendous unmet medical need worldwide.